United Therapeutics
Biotechnology company focused on the development and commercialization of innovative products.
Launch date
Market cap
€13.8b
Enterprise valuation
€11.5b (Public information from Sep 2024)
Share price
$342.59 UTHR
Maryland United States (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.5b | 1.7b | 1.9b | 2.3b | 2.8b | 3.1b | 3.3b |
| % growth | 2 % | 14 % | 15 % | 20 % | 22 % | 8 % | 8 % |
| EBITDA | 672m | 615m | 985m | 1.4b | 1.5b | 1.5b | 1.5b |
| % EBITDA margin | 45 % | 36 % | 51 % | 60 % | 51 % | 50 % | 46 % |
| Profit | 515m | 476m | 727m | 985m | 1.2b | 1.3b | 1.3b |
| % profit margin | 35 % | 28 % | 38 % | 42 % | 42 % | 43 % | 41 % |
| EV / revenue | 3.9x | 5.7x | 6.5x | 3.5x | 4.9x | 4.2x | 3.5x |
| EV / EBITDA | 8.5x | 15.7x | 12.7x | 5.8x | 9.5x | 8.4x | 7.7x |
| R&D budget | 358m | 540m | 323m | 408m | - | - | - |
| R&D % of revenue | 24 % | 32 % | 17 % | 18 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
Recent News about United Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by United Therapeutics
Edit
ACQUISITION by United Therapeutics Apr 2018
ACQUISITION by United Therapeutics Oct 2023
exited